From: Circulating cell-free DNA-based epigenetic assay can detect early breast cancer
 | Whole set (n = 278) | Training set (n = 167) | Validation set (n = 111) | |
---|---|---|---|---|
Number of samples | HVs | 133 | 80 | 53 |
Patients with BC | 145 | 87 | 58 | |
Mean age (range) | HVs | 45.3 (22–70) | 45.8 (26–70) | 44.5 (22–66) |
Patients with BC | 59.5 (36–81) | 59.8 (36–81) | 59.1 (36–81) | |
Subtype | Luminal | 98 | 58 | 40 |
Triple-negative | 25 | 14 | 11 | |
HER2 | 10 | 6 | 4 | |
Luminal HER2 | 8 | 6 | 2 | |
not assessed (DCIS) | 4 | 3 | 1 | |
Stage | 0 | 4 | 3 | 1 |
I | 47 | 27 | 20 | |
IIA | 31 | 19 | 12 | |
IIB | 22 | 11 | 11 | |
III | 9 | 8 | 1 | |
IV | 32 | 19 | 13 | |
Early BC (Stage0-I) | Luminal | 36 | 22 | 14 |
Triple-negative | 8 | 3 | 5 | |
HER2 | 2 | 2 | 0 | |
Luminal HER2 | 1 | 0 | 1 | |
not assessed (DCIS) | 4 | 3 | 1 |